Next Day Disclosure Return (Equity issuer - changes in issued shares or treasury shares, share buybacks and/or on-market sales of treasury shares)

Equity issuer				Status:		New Submission		
Ocumension Therapeutics (the "Company") (Incorporated in the Cayman Islands with limited liability)								
20 January 2025								
he Stock Exchange of Hong Kong L								
Ordinary shares	Туре	of shares Not	applicable	Listed on the	Listed on the Exchange		Yes	
01477	Desci	ription						
nares or treasury shares		·						
Events		Changes in issued shares (excluding treasury shares)		Changes in treasury shares				
		Number of issued shares (excluding treasury shares)	As a % of existing number of issued shares (excluding treasury shares) before the relevant event (Note 3)	Number of treasury shares	,		Total number of issued shares	
17 January 2025		815,622,5	14	17,192,000			832,814,514	
Issue of new shares or transfer of treasury shares in respect of share awards or options granted to a director of the issuer under a share scheme - new shares involved		1,319,0	0.1617 %		HKD	1.4608		
January 2025								
and 6) 20 January 2025		816,941,5	14	17,192,000			834,133,514	
) a () a	Ocumension Therapeutics (the "C 20 January 2025 Peted by a listed issuer where there had be stock Exchange of Hong Kong L des"). Ordinary shares 01477 nares or treasury shares 17 January 2025 ansfer of treasury shares in respect of granted to a director of the issuer under a	Ocumension Therapeutics (the "Company") (I 20 January 2025 Leted by a listed issuer where there has been a company of the Stock Exchange of Hong Kong Limited (the Ides"). Ordinary shares Ordinary shares Type 01477 Description Events Leted by a listed issuer where there has been a company of the Stock Exchange of Hong Kong Limited (the Ides"). Ordinary shares Type 01477 Description Events January 2025 ansfer of treasury shares in respect of granted to a director of the issuer under a resinvolved Description of the Idea of the	Ocumension Therapeutics (the "Company") (Incorporated in the 20 January 2025 Seted by a listed issuer where there has been a change in its issued the Stock Exchange of Hong Kong Limited (the "Exchange") (the fles"). Ordinary shares Type of shares Not Description Changes in (excluding to shares) Number of issued shares (excluding treasury shares) 17 January 2025 ansfer of treasury shares in respect of granted to a director of the issuer under a res involved D January 2025	Ocumension Therapeutics (the "Company") (Incorporated in the Cayman Islands with limited 20 January 2025 Seted by a listed issuer where there has been a change in its issued shares or treasury shares the Stock Exchange of Hong Kong Limited (the "Exchange") (the "Main Board Rules") or refees"). Ordinary shares Type of shares Ordinary shares Changes in issued shares (excluding treasury shares) Number of issued shares (excluding treasury shares) As a % of existing number of issued shares (excluding treasury shares) before the relevant event (Note 3) 17 January 2025 815,622,514 ansfer of treasury shares in respect of granted to a director of the issuer under a res involved Dianuary 2025	Ocumension Therapeutics (the "Company") (Incorporated in the Cayman Islands with limited liability) 20 January 2025 eted by a listed issuer where there has been a change in its issued shares or treasury shares which is discloseable the Stock Exchange of Hong Kong Limited (the "Exchange") (the "Main Board Rules") or rule 17.27A of the Rules (es"). Ordinary shares Type of shares Not applicable Listed on the 01477 Description Changes in issued shares (excluding treasury shares) Number of issued shares (excluding treasury shares) before the relevant event (Note 3) Number of issued shares (excluding treasury shares) before the relevant event (Note 3) 17 January 2025 1815,622,514 17,192,000 January 2025	Ocumension Therapeutics (the "Company") (Incorporated in the Cayman Islands with limited liability) 20 January 2025 Seted by a listed issuer where there has been a change in its issued shares or treasury shares which is discloseable pursuant to rull the Stock Exchange of Hong Kong Limited (the "Exchange") (the "Main Board Rules") or rule 17.27A of the Rules Governing the les"). Ordinary shares Type of shares Not applicable Listed on the Exchange Othanges in issued shares (excluding treasury shares) Changes in issued shares (excluding treasury shares) Number of issued shares (excluding treasury shares) lessed shares (excluding treasury shares) lessed shares (excluding treasury shares) before the relevant event (Note 3) 17 January 2025 815,622,514 Number of treasury shares in respect of granted to a director of the issuer under a ess involved Danuary 2025	Ocumension Therapeutics (the "Company") (Incorporated in the Cayman Islands with limited liability) 20 January 2025 Seted by a listed issuer where there has been a change in its issued shares or treasury shares which is discloseable pursuant to rule 13.25A of the Stock Exchange of Hong Kong Limited (the "Exchange") (the "Main Board Rules") or rule 17.27A of the Rules Governing the Listing of Siles"). Ordinary shares Type of shares Not applicable Listed on the Exchange Yes O1477 Description Theresoury shares Changes in issued shares (excluding treasury shares) Number of issued shares (excluding treasury shares) As a % of existing number of issued shares (excluding treasury shares) before the relevant event (Note 3) Issuel selling price per share (Note 4) Interval years (N	

Page 1 of 6 v 1.3.0

Remarks:

The exercise price of the share options exercised is US\$0.188 as determined at the date of grant, which equals to HK\$1.4608 based on the exchange rate of US\$1.00 = HK\$7.7702.

Page 2 of 6 v 1.3.0

Confirmation

Pursuant to Main Board Rule 13.25C / GEM Rule 17.27C, we hereby confirm to the best knowledge, information and belief that, in relation to each issue of shares or sale or transfer of treasury shares as set out in Section I, it has been duly authorised by the board of directors of the listed issuer and carried out in compliance with all applicable listing rules, laws and other regulatory requirements and, insofar as applicable:

(Note 7)

- (i) all money due to the listed issuer in respect of the issue of shares, or sale or transfer of treasury shares has been received by it;
- (ii) all pre-conditions for the listing imposed by the Main Board Rules / GEM Rules under "Qualifications of listing" have been fulfilled;
- (iii) all (if any) conditions contained in the formal letter granting listing of and permission to deal in the securities have been fulfilled;
- (iv) all the securities of each class are in all respects identical (Note 8);
- (v) all documents required by the Companies (Winding Up and Miscellaneous Provisions) Ordinance to be filed with the Registrar of Companies have been duly filed and that compliance has been made with all other legal requirements;
- (vi) all the definitive documents of title have been delivered/are ready to be delivered/are being prepared and will be delivered in accordance with the terms of issue, sale or transfer;
- (vii) completion has taken place of the purchase by the issuer of all property shown in the listing document to have been purchased or agreed to be purchased by it and the purchase consideration for all such property has been duly satisfied; and
- (viii) the trust deed/deed poll relating to the debenture, loan stock, notes or bonds has been completed and executed, and particulars thereof, if so required by law, have been filed with the Registrar of Companies.

Notes to Section I:

- 1. Please insert the closing balance date of the last Next Day Disclosure Return published pursuant to Main Board Rule 13.25A / GEM Rule 17.27A or Monthly Return pursuant to Main Board Rule 13.25B / GEM Rule 17.27B, whichever is the later.
- 2. Please set out all changes in issued shares or treasury shares requiring disclosure pursuant to Main Board Rule 13.25A / GEM Rule 17.27A together with the relevant dates of changes. Each category will need to be disclosed individually with sufficient information to enable the user to identify the relevant category in the listed issuer's Monthly Return. For example, multiple issues of shares as a result of multiple exercises of share options under the same share option scheme or of multiple conversions under the same convertible note must be aggregated and disclosed as one category. However, if the issues resulted from exercises of share options under 2 share option schemes or conversions of 2 convertible notes, these must be disclosed as 2 separate categories.
- 3. The percentage change in the number of issued shares (excluding treasury shares) of the listed issuer is to be calculated by reference to the opening balance of the number of issued shares (excluding treasury shares) being disclosed in this Next Day Disclosure Return.

Page 3 of 6 v 1.3.0

- 4. In the case of a share repurchase or redemption, the "issue/ selling price per share" shall be construed as "repurchase price per share" or "redemption price per share".
 - Where shares have been issued/ sold/ repurchased/ redeemed at more than one price per share, a volume-weighted average price per share should be given.
- 5. The closing balance date is the date of the last relevant event being disclosed.
- 6. For repurchase or redemption of shares, disclosure is required when the relevant event has occurred (subject to the provisions of Main Board Rules 10.06(4)(a), 13.25A and 13.31 / GEM Rules 13.13(1), 17.27A and 17.35), even if the repurchased or redeemed shares have not yet been cancelled.
 - If repurchased or redeemed shares are to be cancelled upon settlement of such repurchase or redemption after the closing balance date, they shall remain part of the issued shares as at the closing balance date in Part A. Details of these repurchased or redeemed shares shall be disclosed in Part B.
- 7. Items (i) to (viii) are suggested forms of confirmation. The listed issuer may amend the item(s) that is/are not applicable to meet individual cases.
- 8. "Identical" means in this context:
 - the securities are of the same nominal value with the same amount called up or paid up;
 - they are entitled to dividend/interest at the same rate and for the same period, so that at the next ensuing distribution, the dividend/interest payable per unit will amount to exactly the same sum (gross and net); and
 - they carry the same rights as to unrestricted transfer, attendance and voting at meetings and rank pari passu in all other respects.

Page 4 of 6 v 1.3.0

Section II must also be completed by a listed issuer where it has made a repurchase of shares which is discloseable under Main Board Rule 10.06(4)(a) / GEM Rule 13.13(1).

Repurchase report Not applicable

Page 5 of 6 v 1.3.0

Section III must also be completed by a listed issuer where it has made a sale of treasury shares on the Exchange or any other stock exchange on which the issuer is listed which is discloseable under Main Board Rule 10.06B / GEM Rule 13.14B.

Report of on-market sale of treasury shares

Not applicable

Submitted by:	Lian Yong CHEN
	(Name)
Title:	Director
	(Director, Secretary or other Duly Authorised Officer)

Page 6 of 6 v 1.3.0